|
1
|
Rosenberg AE: WHO classification of soft
tissue and bone, fourth edition: Summary and commentary. Curr Opin
Oncol. 25:571–573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Azvolinsky A: Heterogeneous and rare:
Toward histology-specific treatment of soft-tissue sarcoma. J Natl
Cancer Inst. 108:djw1612016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ
and Chen YT: Cancer/testis antigens: An expanding family of targets
for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burgess M and Tawbi H: Immunotherapeutic
approaches to sarcoma. Curr Treat Options Oncol. 16:262015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Endo M, de Graaff MA, Ingram DR, Lim S,
Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ and
Nielsen TO: NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod
Pathol. 28:587–595. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lai JP, Robbins PF, Raffeld M, Aung PP,
Tsokos M, Rosenberg SA, Miettinen MM and Lee CC: NY-ESO-1
expression in synovial sarcoma and other mesenchymal tumors:
Significance for NY-ESO-1-based targeted therapy and differential
diagnosis. Mod Pathol. 25:854–858. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robbins PF, Kassim SH, Tran TL, Crystal
JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR,
Sherry RM, et al: A pilot trial using lymphocytes genetically
engineered with an NY-ESO-1-reactive T-cell receptor: Long-term
follow-up and correlates with response. Clin Cancer Res.
21:1019–1027. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fernandez-Viña MA, Falco M, Sun Y and
Stastny P: DNA typing for HLA class I alleles: I. Subsets of HLA-A2
and of -A28. Hum Immunol. 33:163–173. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weon JL and Potts PR: The MAGE protein
family and cancer. Curr Opin Cell Biol. 37:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saito T, Wada H, Yamasaki M, Miyata H,
Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M and Doki Y: High
expression of MAGE-A4 and MHC class I antigens in tumor cells and
induction of MAGE-A4 immune responses are prognostic markers of
CHP-MAGE-A4 cancer vaccine. Vaccine. 32:5901–5907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kageyama S, Ikeda H, Miyahara Y, Imai N,
Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, et al:
Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced
lymphocytes in patients with recurrent esophageal cancer. Clin
Cancer Res. 21:2268–2277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balafoutas D, zur Hausen A, Mayer S,
Hirschfeld M, Jaeger M, Denschlag D, Gitsch G, Jungbluth A and
Stickeler E: Cancer testis antigens and NY-BR-1 expression in
primary breast cancer: Prognostic and therapeutic implications. BMC
Cancer. 13:2712013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jungbluth AA, Antonescu CR, Busam KJ,
Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M and Old
LJ: Monophasic and biphasic synovial sarcomas abundantly express
cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J
Cancer. 94:252–256. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pollack SM, Jungbluth AA, Hoch BL, Farrar
EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad
EU III, et al: NY-ESO-1 is a ubiquitous immunotherapeutic target
antigen for patients with myxoid/round cell liposarcoma. Cancer.
118:4564–4570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hemminger JA and Iwenofu OH: NY-ESO-1 is a
sensitive and specific immunohistochemical marker for myxoid and
round cell liposarcomas among related mesenchymal myxoid neoplasms.
Mod Pathol. 26:1204–1210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iura K, Maekawa A, Kohashi K, Ishii T,
Bekki H, Otsuka H, Yamada Y, Yamamoto H, Harimaya K, Iwamoto Y and
Oda Y: Cancer-testis antigen expression in synovial sarcoma:
NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol. 61:130–139. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yabe H, Tsukahara T, Kawaguchi S, Wada T,
Torigoe T, Sato N, Terai C, Aoki M, Hirose S, Morioka H and Yabe H:
Prognostic significance of HLA class I expression in Ewing's
sarcoma family of tumors. J Surg Oncol. 103:380–385. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsukahara T, Kawaguchi S, Torigoe T,
Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M,
Nagoya S, et al: Prognostic significance of HLA class I expression
in osteosarcoma defined by anti-pan HLA class I monoclonal
antibody, EMR8-5. Cancer Sci. 97:1374–1380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gooden MJ, de Bock GH, Leffers N, Daemen T
and Nijman HW: The prognostic influence of tumour-infiltrating
lymphocytes in cancer: A systematic review with meta-analysis. Br J
Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujii H, Arakawa A, Utsumi D, Sumiyoshi S,
Yamamoto Y, Kitoh A, Ono M, Matsumura Y, Kato M, Konishi K, et al:
CD8+ tumor-infiltrating lymphocytes at primary sites as
a possible prognostic factor of cutaneous angiosarcoma. Int J
Cancer. 134:2393–2402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oike N, Kawashima H, Ogose A, Hotta T,
Hatano H, Ariizumi T, Sasaki T, Yamagishi T, Umezu H and Endo N:
Prognostic impact of the tumor immune microenvironment in synovial
sarcoma. Cancer Sci. 109:3043–3054. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshida N, Abe H, Ohkuri T, Wakita D, Sato
M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H and
Nishimura T: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis
antigens and T cell infiltration in non-small cell lung carcinoma
and their prognostic significance. Int J Oncol. 28:1089–1098.
2006.PubMed/NCBI
|
|
24
|
Bergeron A, Picard V, LaRue H, Harel F,
Hovington H, Lacombe L and Fradet Y: High frequency of MAGE-A4 and
MAGE-A9 expression in high-risk bladder cancer. Int J Cancer.
125:1365–1371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Doyle JM, Gao J, Wang J, Yang M and Potts
PR: MAGE-RING protein complexes comprise a family of E3 ubiquitin
ligases. Mol Cell. 39:963–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
